USCWA
GNOM icon

U.S. Capital Wealth Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$668K Buy
15,270
+2,625
+21% +$121K 0.02% 611
2025
Q4 		$575K Buy
+12,645
New +$561K 0.02% 626

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
AA
Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
SWA
Sightline Wealth Advisors Groton, Connecticut $273M AUM 18.08% 1-Year Est. Return

U.S. Capital Wealth Advisors's GNOM Position: Q1 2026 in Review

U.S. Capital Wealth Advisors increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 21% in Q1 2026, buying an estimated $121K and bringing the position to 15,270 shares worth $668K. The position accounts for 0.02% of the portfolio, ranked #611.

U.S. Capital Wealth Advisors first reported a position in GNOM in Q4 2025 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

  • U.S. Capital Wealth Advisors held 15,270 shares of Global X Genomics & Biotechnology ETF worth $668K as of Q1 2026.
  • U.S. Capital Wealth Advisors bought 2,625 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $121K.
  • Global X Genomics & Biotechnology ETF made up 0.02% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #611 holding.
  • U.S. Capital Wealth Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2025 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.